These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 16313352)

  • 1. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC; Crotti TN; Goldring SR; Gravallese EM
    Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L; Schwarz EM; Boyce BF
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
    Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J; Tovar I; Martínez P
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract]   [Full Text] [Related]  

  • 11. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract]   [Full Text] [Related]  

  • 13. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between interferon and other cytokine systems in bone metabolism.
    Takayanagi H; Sato K; Takaoka A; Taniguchi T
    Immunol Rev; 2005 Dec; 208():181-93. PubMed ID: 16313349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
    Ritchlin CT; Schwarz EM; O'Keefe RJ; Looney RJ
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):276-84. PubMed ID: 15615495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.